GlassScriptPhysician profile
Adrian V Pop
NPI 1073642609
$13,429.80
in general payments reported to CMS, 2019-2025
22 companies · $1,951 in 2025
The $1,951 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,326 · 2020: $359 · 2021: $1,193 · 2022: $5,730 · 2023: $2,077 · 2024: $794 · 2025: $1,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,464 · Travel and Lodging: $1,214 · Entertainment: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,463.87 |
| Travel and Lodging | $1,213.51 |
| Entertainment | $144.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $4,925.58 | 2022 | |
| Alcon Vision LLC | $2,796.76 | 2019-2025 | Wavelight Refractive Suite, Rocklatan, Rhopressa |
| Bausch & Lomb Americas INC. | $1,231.04 | 2022-2025 | Xiidra, Miebo, Alden Scleral Zenlens |
| Dompe US, INC. | $905.17 | 2021-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $814.29 | 2019-2021 | |
| Sight Sciences, INC. | $499.52 | 2021-2022 | |
| Glaukos Corporation | $447.99 | 2020-2025 | Idosetr, Istent Infinite |
| Abbvie INC. | $331.95 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $267.11 | 2019-2025 | |
| Allergan, INC. | $266.76 | 2020-2022 | |
| Optos, INC. | $144.65 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Biotissue Holdings INC. | $136.66 | 2019-2022 | |
| Visioneering Technologies, INC. | $128.84 | 2019-2024 | |
| Genzyme Corporation | $113.38 | 2019 | |
| Optovue, INC. | $85.66 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $80.85 | 2025 | Myday Contact Lens |
| Rxsight INC | $75.10 | 2025 | Rxsight Injector Handpiece, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Shire North American Group INC | $55.60 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $34.04 | 2021 | |
| Oyster Point Pharma, INC. | $33.24 | 2024 | Ryzumvi, Tyrvaya |
| Alcon Research LLC | $31.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Pop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.